Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes

…, M Ezrokhi, D Rutty, ZJ Ma, RE Scranton - Diabetes …, 2010 - Am Diabetes Assoc
OBJECTIVE Quick-release bromocriptine (bromocriptine-QR), a D2 dopamine receptor
agonist, is indicated as a treatment for type 2 diabetes. The Cycloset Safety Trial, a 52-week, …

The association between statins and cancer incidence in a veterans population

WR Farwell, RE Scranton, EV Lawler… - Journal of the …, 2008 - academic.oup.com
Background Meta-analyses of trials of 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors
or statins for cardiovascular disease prevention have failed to show any statistically …

Statins and prostate cancer diagnosis and grade in a veterans population

WR Farwell, LW D'Avolio, RE Scranton… - Journal of the …, 2011 - academic.oup.com
Background Although prostate cancer is commonly diagnosed, few risk factors for high-grade
prostate cancer are known and few prevention strategies exist. Statins have been …

Statin use and fracture risk: study of a US veterans population

RE Scranton, M Young, E Lawler… - Archives of internal …, 2005 - jamanetwork.com
Background Whether statins reduce the risk of fractures is still contested. Several studies
support a favorable association, whereas post hoc analyses of statin-randomized trials have …

Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management

RE Scranton, I Goldstein… - The journal of sexual …, 2013 - academic.oup.com
Introduction Optimal pharmacologic management of diseases comorbid with erectile dysfunction
(ED), such as cardiovascular disease, depression, diabetes, dyslipidemia, hypertension…

[HTML][HTML] Timed bromocriptine-QR therapy reduces progression of cardiovascular disease and dysglycemia in subjects with well-controlled type 2 diabetes mellitus

…, JM Gaziano, L Blonde, A Vinik, RE Scranton… - Journal of Diabetes …, 2015 - hindawi.com
Background. Type 2 diabetes (T2DM) patients, including those in good glycemic control,
have an increased risk of cardiovascular disease (CVD). Maintaining good glycemic control …

[HTML][HTML] A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either …

RE Scranton, JM Gaziano, D Rutty, M Ezrokhi… - BMC endocrine …, 2007 - Springer
Background Cycloset™ is a quick-release formulation of bromocriptine mesylate, a dopamine
agonist, which in animal models of insulin resistance and type 2 diabetes acts centrally to …

Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents

AI Vinik, AH Cincotta, RE Scranton, N Bohannon… - Endocrine Practice, 2012 - Elsevier
Scranton has served within the past five years as consultant or advisor for Berlex, Sanofi-Aventis,
and a lecturer for KOS; a scientific investigator for Pfizer Inc, Merck, Pliva, Berlex …

Effect of treating erectile dysfunction on management of systolic hypertension

RE Scranton, E Lawler, M Botteman… - The American journal of …, 2007 - Elsevier
Erectile dysfunction (ED) is a prevalent condition and a predictor of future cardiovascular
events. Screening and treatment of ED may improve management of cardiovascular risk factors…

Cardiovascular benefit of magnitude of low-density lipoprotein cholesterol reduction: a comparison of subgroups by age

CR Rahilly-Tierney, EV Lawler, RE Scranton… - Circulation, 2009 - Am Heart Assoc
Background— We examined the effect of the magnitude of low-density lipoprotein cholesterol
(LDL-C) reduction across subjects of various ages in a retrospective cohort study. Methods …